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Abstract 
Objectives: Pneumococcal vaccination is recommended for patients requiring treatment with 
immunosuppressive drugs. The aim of this report is to describe unusually severe adverse 
reactions to pneumococcal vaccination in each of seven consecutive patients with cryopyrin 
associated periodic syndromes (CAPS). 
Methods: Seven consecutive patients with CAPS were vaccinated with pneumococcal 
polysaccharide or conjugate vaccines. Clinical information was collected retrospectively. 
Results: Within a few hours after the vaccination, all seven patients developed severe local 
reactions at the injection site. Two patients had to be hospitalized for systemic reactions 
including fever. All symptoms resolved in a period of 3 to 17 days. 
Conclusion: Pneumococcal vaccines can trigger a severe local and systemic inflammatory 
reaction in patients with CAPS and possibly patients with other autoinflammatory diseases. 
Careful consideration is warranted when implicating current EULAR immunization guidelines 
in this patient population. 
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Cryopyrin-Associated Periodic Syndromes (CAPS), specifically Familial Cold 
Autoinflammatory Syndrome (FCAS), Muckle-Wells Syndrome (MWS), and Neonatal Onset 
Multisystem Inflammatory Disease (NOMID) are a group of rare hereditary autoinflammatory 
periodic fever syndromes associated with mutations in the NLRP3 gene, whose encoded 
product interacts with other intracellular proteins to form the NLRP3 inflammasome (1;2). 
Mutations in the NLRP3 gene cause a constitutive activation of the NLRP3 inflammasome. 
Toll-like receptors (TLR) detect intracellular and extracellular pathogens and danger signals 
and their signalling enhances the synthesis of pro-interleukin-1β (IL-1β). Abnormally 
enhanced activation of the inflammasome in CAPS results in the cleavage of pro-IL-1β and 
thus in the overproduction of active IL-1β. Following the identification of the genetic basis for 
CAPS and the common pathway of IL-1β activation, new approaches to treat these 
conditions have been licensed. Among these is canakinumab, a monoclonal antibody that 
specifically blocks IL-1β (3).  
Infections with Streptococcus pneumoniae represent a significant cause of morbidity and 
mortality (4;5). The European League Against Rheumatism (EULAR) therefore strongly 
recommends consideration of the 23-valent polysaccharide pneumococcal vaccine (23-PPV) 
in patients with periodic fever syndromes (6). Similarly, the Advisory Committee on 
Immunization Practices to the Center for Disease Control and Prevention (CDC) 
recommends pneumococcal vaccination to patients with diseases requiring treatment with 
immunosuppressive drugs, including long-term systemic corticosteroids (4). 
 
Patients and Methods 
The authors followed these recommendations and consecutively vaccinated seven CAPS 
patients with pneumococcal vaccines. All seven patients developed unusually severe local 
and/or systemic inflammatory adverse reactions. The purpose of this manuscript is to report 
and interpret these events. 
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Results 
All cases are summarized in the Table. Case 1 is that of a 43 year old female with MWS who 
received a Pneumovax II vaccination in January 2014, the same day as her next 
canakinumab injection of 150mg was due. Within a few hours of having the vaccination she 
experienced local injection site symptoms of swelling, redness and pain. On the subsequent 
day, she developed fever, profuse shivering and sweating, nausea and vomiting. By the 
fourth day she had developed a severe headache associated with neck stiffness and 
photophobia, and continued to have fever along with a florid red rash covering much of the 
arm where the vaccine had been administered. The patient was admitted to her local hospital 
that evening with a diagnosis of presumed viral meningitis. Lumbar puncture revealed 
elevated white cells (96 per cubic millimetre, neutrophils 84%), normal glucose 2.3 mmol/L 
and elevated protein at 0.79 g/L in the CSF. Her CRP taken on admission was 63mg/L. She 
remained hospitalized for 18 days, during which the symptoms gradually improved; rash on 
the arm was still present at discharge.  
Case 2 is that of a 20 year old female with NOMID who received a Pneumovax II vaccination 
on the same day as case 1, along with her next scheduled 300 mg canakinumab injection. 
Within hours of having the vaccination, she experienced injection site symptoms of slight 
swelling, a rash just below the injection site and pain. Over the next few days the rash spread 
down her left arm and became more painful. She began experiencing fever. On the eighth 
day after the vaccination, the patient was admitted to her local hospital with cellulitis involving 
the vaccinated left arm. She was discharged from hospital at day 13, describing her rash as 
‘dramatically improved’, with residual discoloration, no redness but some itch at times. 
The authors subsequently vaccinated five additional CAPS patients, all of which developed 
severe local inflammation. Cases 1 to 6 were in stable remission while receiving 
canakinumab, whereas case 7 had daily flares and had not received any 
immunosuppression at the time of vaccination. The local adverse reaction to the 23-PPV was 
similar in all patients and developed a few hours after the injection with pain, redness and 
local swelling; urticarial lesions were not reported.  
 
Several aspects are remarkable. The reaction occurred with pneumococcal vaccines from 
three different manufacturers and in patients with different CAPS phenotypes. Four 
vaccination reactions occurred in temporal association with concomitant co-injections of 
canakinumab, two other vaccination reactions were separated by 15 days from last 
canakinumab dose, but in case 7, a similar event was also observed prior to any 
canakinumab therapy. Lastly it should be noted, that some patients had been vaccinated with 
a variety of other vaccines without complications.  
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Discussion 
We report unusually severe adverse reactions in each of seven consecutive patients with 
CAPS who received pneumococcal vaccination, requiring hospitalization in two cases. The 
safety of pneumococcal vaccination has previously been established in a number of 
autoimmune diseases, including rheumatoid arthritis, juvenile arthritis, and systemic lupus 
erythematosus (7). Local or systemic adverse events and disease flares were reported at 
only a low frequency (8). Of note, fever (>37.8°C) was reported in less than 3% of vaccinated 
normal subjects (8). In healthy subjects, cellulitis-like reactions were only rarely reported post 
marketing (9). When approximately 43 million doses were distributed, the annual reporting 
rate of cellulitis-like reactions was 2.5/100’000 doses, and the median hospitalisation time 
was two days after vaccine administration (9). Our observations suggest that the frequency 
and intensity of vaccine reactions may be greater in CAPS than in populations of patients 
without this hereditary periodic fever syndrome. 
 
We noted vaccine reactions with preparations from three different manufacturers. Some of 
these (Pneumovax 23 and Pneumovax II) contain phenol as a preservative. Phenol however 
has only low immunogenic properties and is also used in the influenza and Haemophilus 
influenzae vaccines. Our subjects had however previously reported to have tolerated the 
latter vaccines well and phenol is not a component of Prevenar (Prevnar) 13, a vaccine to 
which one of our cases reacted. Aluminum is another frequently used vaccine constituent in 
which it is used as an adjuvant. The NLRP3 inflammasome plays a crucial role in the 
immunostimulatory property of aluminium (10). Although Prevenar does contain aluminium, 
Pneumovax 23 and Pneumovax II do not. Four subjects have received canakinumab in 
conjunction with the pneumococcal vaccine. It is however unlikely that the observed 
reactions are caused by canakinumab co-administration because an adverse reaction was 
also observed in two patients 15 days after the last canakinumab injection and in one patient 
who had had no exposure to canakinumab (case 7). In summary, the adverse reactions 
cannot be explained by the presence of a preservative, the presence of an adjuvant, or the 
preparation/ batch of a particular manufacturer. Thus the vaccine reaction appears to be 
specific for pneumococcal antigens. 
 
Pneumococcal polysaccharides (present in Pneumovax 23 and Pneumovax II) and 
pneumococcal conjugates (present in Prevenar) can activate inflammatory gene transcription 
by stimulating TLR2 and TLR4 (5;11). Enhanced TLR triggering by pneumococcal vaccine 
components with subsequent inflammasome hyperactivation in CAPS patients with NLRP-3 
mutations may best explain the high incidence rate of this adverse event, its rapid onset, 
severity, and the systemic nature of the reaction. It is interesting in this context that case 1 
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had developed meningitis, a complication that may reflect activation of the underlying CAPS. 
Severe local and systemic reactions to consecutive applications of Pneumovax have also 
been described in patients with Behçets disease (BD) (12), a condition that has also been 
proposed to result from aberrant activation of the inflammasome (13). In some of these BD 
patients who had reacted to pneumococcal vaccination (12), the vaccine had elicited 
pseudofolliculitis (unpublished observation of the corresponding author, documented in 
Figure 1 of the online supplement). Thus, it seems that pneumococcal vaccines can trigger 
flares of the autoinflammatory disease, which then could also contribute to the observed 
systemic inflammation. 
If pneumococcal TLR agonists enhance IL-1β cleavage in patients predisposed to 
hyperactivation of the inflammasome, why does then canakinumab not completely block the 
clinical manifestation of the resulting inflammation? One hypothesis is, that the activated 
inflammasome can mediate proinflammatory pathways independent of IL-1β cleavage in 
terms of IL-18, pyroptosis and eicosanoid production (14), and that the vaccine reaction is 
mediated by these IL-1β-independent pathways. Alternatively, local vaccine reactions could 
be explained by insufficient canakinumab concentrations at the injection site of the vaccine. 
 
The risk of adverse vaccine reactions must clearly be weighed against the risk of 
pneumococcal infections (15). Mice with dysfunctional NLRP3 signalling are more 
susceptible to pneumococcal pneumonia (16) and a functional inflammasome is important for 
the generation of protective antibodies against pneumococci (17;18). Intact IL-1 signalling is 
also important in the normal host response to pneumococcal infection, which is illustrated in 
patients with IRAK4 deficiency who have increased risk of streptococcal infection, 
presumably due to aberrant IL-1 receptor responses. The implications of the inflammasome 
in the clinical protection against pneumococci in people however remain unclear (5). 
Although vaccination protocols for immunosuppressed persons mostly result in titers that are 
considered protective, a clinical protection of pneumococcal vaccines in persons treated with 
biological agents has not yet been demonstrated. By balancing the observed vaccine 
reactions against the known benefits of pneumococcal vaccines, the authors have 
momentarily stopped to routinely vaccinate CAPS patients against pneumococci in their 
clinics until further data become available. 
 
This case series suggests that the safety of pneumococcal vaccinations in CAPS patients be 
further investigated and those patients be more closely monitored after vaccination. The 
observational, non-experimental nature of this case series also accounts for the lack of 
systematic and detailed follow-up. 
Walker UA, Pneumococcal vaccines in CAPS, page 7 
 
The β-confident registry is an open-label, multi-centre, long-term, prospective, observational 
study (CTN: NCT01213641) that includes CAPS patients treated with canakinumab. The 
registry has completed enrolment in December 2014 and will complete up to six years of 
follow up, with a minimum of one year follow up, in December 2015. The full analysis of this 
registry data is expected to include analyses of prior and concurrent immunisation 
experience. 
 
In conclusion, pneumococcal vaccines can trigger severe local and systemic inflammatory 
reaction in CAPS patients, and possibly patients with other autoinflammatory diseases. Until 
further data become available, the potential benefits of pneumococcal vaccines should be 
carefully balanced against their safety concerns.  
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Table 1. Clinical characteristics of CAPS patients who developed severe inflammation after pneumococcal vaccination  
Case Nr. 
Age, 
gender 
Clinical 
presen-
tation 
NLRP3 
Mutation 
CAPS 
duration 
CAPS 
treatment 
Vaccine/ 
manufacturer 
Previous 
uneventful 
vaccines  
Days since last 
canakinumab 
Days 
until 
onset  
Local 
symptoms  
Systemic 
reaction 
 
Treatment of 
vaccine reaction 
Days until 
resolution 
Case 1 
43 years, 
female 
MWS T348M 43 years Canakinumab 
150 mg  
every 8 weeks 
Pneumovax II 
/ Sanofi 
Pasteur 
Nil  New canakinumab dose 
given on day of 
vaccination (63 days 
since previous dose) 
0 Swelling, 
rubor, 
dolor, 
calor 
Fever, 
nausea, 
headache, 
stiff neck 
Antibiotics (i.v.) 
Prednisolone 
Paracetamol 
 
17 
Case 2 
20 years, 
female 
NOMID L632F 20 years Canakinumab 
300 mg  
every 8 weeks 
Pneumovax II/ 
Sanofi Pasteur 
Influenza New canakinumab dose 
given on day of 
vaccination (56 days 
since previous dose) 
0 Swelling, 
rubor, 
dolor, 
calor 
Fever   Ibuprofen 12 
Case 3 
26 years, 
female 
NOMID A352T 26 years Canakinumab 
300 mg  
every 8 weeks 
Pneumovax II/ 
Sanofi Pasteur 
Nil New canakinumab dose 
given on day of 
vaccination (49 days 
since previous dose) 
0 Swelling, 
rubor, 
dolor, 
calor 
Not known Antibiotics (i.v., oral) 
Local therapy 
14 
Case 4 
43 years, 
male 
MWS T348M 43 years Canakinumab 
150 mg  
every 8 weeks 
Pneumovax II/ 
Sanofi Pasteur 
Influenza New canakinumab dose 
given on day of 
vaccination (63 days 
since previous dose) 
0 dolor None Nonsteroidal anti-
inflammatory drugs 
Local therapy 
4 
Case 5 
24 years, 
female 
MWS E311K 10 years Canakinumab 
150 mg  
every 8 weeks 
Pneumovax 
23/ Merck 
Influenza, 
HiB 
Canakinumab was given 
15 days prior to 
vaccination 
0 Swelling, 
rubor, 
dolor, 
calor 
None Local therapy 3 
Case 6 
52 years, 
female 
MWS E 311K 51 years Canakinumab 
300 mg  
every 8 weeks 
Pneumovax 
23/ Merck  
Influenza Canakinumab was given 
15 days prior to 
vaccination 
0 Swelling, 
rubor, 
dolor, 
calor 
None Local therapy 10 
Case 7 
7 years, 
female 
FCAS No 
known 
mutation 
7 years None Prevenar 13/ 
Wyeth  
Diphtheria 
Polio 
Tetanus 
No prior or concomitant 
canakinumab 
0 Swelling, 
rubor, 
dolor, 
calor 
None Local therapy 4 
Walker UA, Pneumococcal vaccines in CAPS, page 9 
 
References 
 (1)  Cuisset L, Jeru I, Dumont B, Fabre A, Cochet E, Le BJ et al. Mutations in the 
autoinflammatory cryopyrin-associated periodic syndrome gene: epidemiological study and 
lessons from eight years of genetic analysis in France. Ann Rheum Dis 2011;70:495-9.  
 (2)  Neven B, Prieur AM, Quartier dit MP. Cryopyrinopathies: update on pathogenesis and 
treatment. Nat Clin Pract Rheumatol 2008;4:481-9.  
 (3)  Curran MP. Canakinumab: in patients with cryopyrin-associated periodic syndromes. 
BioDrugs 2012;26:53-9.  
 (4)  Updated recommendations for prevention of invasive pneumococcal disease among adults 
using the 23-valent pneumococcal polysaccharide vaccine (PPSV23). MMWR Morb Mortal 
Wkly Rep 2010;59:1102-6.  
 (5)  van der Poll T, Opal SM. Pathogenesis, treatment, and prevention of pneumococcal 
pneumonia. Lancet 2009;374:1543-56.  
 (6)  van Assen S., Agmon-Levin N, Elkayam O, Cervera R, Doran MF, Dougados M et al. EULAR 
recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic 
diseases. Ann Rheum Dis 2011;70:414-22.  
 (7)  Elkayam O, Paran D, Caspi D, Litinsky I, Yaron M, Charboneau D et al. Immunogenicity and 
safety of pneumococcal vaccination in patients with rheumatoid arthritis or systemic lupus 
erythematosus. Clin Infect Dis 2002;34:147-53.  
 (8)  Musher DM, Manof SB, Liss C, McFetridge RD, Marchese RD, Bushnell B et al. Safety and 
antibody response, including antibody persistence for 5 years, after primary vaccination or 
revaccination with pneumococcal polysaccharide vaccine in middle-aged and older adults. J 
Infect Dis 2010;201:516-24.  
 (9)  Burwen DR, La VL, Braun MM, Houck P, Ball R. Evaluating adverse events after vaccination 
in the Medicare population. Pharmacoepidemiol Drug Saf 2007;16:753-61.  
 (10)  Eisenbarth SC, Colegio OR, O'Connor W, Sutterwala FS, Flavell RA. Crucial role for the 
Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature 
2008;453:1122-6.  
 (11)  Sen G, Khan AQ, Chen Q, Snapper CM. In vivo humoral immune responses to isolated 
pneumococcal polysaccharides are dependent on the presence of associated TLR ligands. J 
Immunol 2005;175:3084-91.  
Walker UA, Pneumococcal vaccines in CAPS, page 10 
 
 (12)  Hugle T, Bircher A, Walker UA. Streptococcal hypersensitivity reloaded: severe inflammatory 
syndrome in Behcet's disease following 23-valent polysaccharide Streptococcus pneumoniae 
vaccine. Rheumatology (Oxford) 2012;51:761-2.  
 (13)  Kastner DL, Aksentijevich I, Goldbach-Mansky R. Autoinflammatory disease reloaded: a 
clinical perspective. Cell 2010;140:784-90.  
 (14)  Lamkanfi M, Dixit VM. Mechanisms and functions of inflammasomes. Cell 2014;157:1013-22.  
 (15)  Centers for Disease Control and Prevention. Prevention of Pneumococcal Disease. 
Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 
Morb Mortal Wkly Rep 1997;46:1-25.  
 (16)  Witzenrath M, Pache F, Lorenz D, Koppe U, Gutbier B, Tabeling C et al. The NLRP3 
inflammasome is differentially activated by pneumolysin variants and contributes to host 
defense in pneumococcal pneumonia. J Immunol 2011;187:434-40.  
 (17)  McNeela EA, Burke A, Neill DR, Baxter C, Fernandes VE, Ferreira D et al. Pneumolysin 
activates the NLRP3 inflammasome and promotes proinflammatory cytokines independently 
of TLR4. PLoS Pathog 2010;6:e1001191.  
 (18)  Taillardet M, Haffar G, Mondiere P, Asensio MJ, Pleau-Pison T, Burdin N et al. Toll-like 
receptor agonists allow generation of long-lasting antipneumococcal humoral immunity in 
response to a plain polysaccharidic vaccine. J Infect Dis 2010;202:470-9.  
 
 
 
